BACKGROUND: Experimental studies suggest that the infiltration of activated T cells into the allograft, the key event in the development of acute renal allograft rejection, depends on the expression of chemokines and their interaction with chemokine receptors expressed on T cells. METHODS: For a more detailed comprehension of the pathogenesis of T-cell recruitment in human acute rejection, the in situ expression of chemokines and chemokine receptors in allografts of 26 patients between day 3 and 9 after renal transplantation was examined in the present prospective study. RESULTS: Immunohistochemical staining showed a significantly increased number of CXCR3 (P<0.01) and CCR5 positive T cells (P<0.01) in the tubulointerstitium of patients with acute allograft rejection according to Banff grade Ia-IIb. Likewise the intrarenal RNA expression of the CXCR3 ligands IP-10 (5.2-fold) and I-TAC (7.2-fold) and the CCR5 ligand RANTES (5.7-fold), was significantly up-regulated in rejecting organs. In situ hybridization revealed that IP-10 but not I-TAC was predominantly expressed by infiltrating leukocytes in the tubulointerstitial area, co-localizing with CXCR3 positive T cells. To a lesser degree expression by tubular cells could be detected, providing a possible explanation for the increased urinary IP-10 excretion we found in patients with rejecting organs. CONCLUSIONS: These data from a prospective, biopsy-controlled study indicate that the local expression of IP-10 and RANTES leads to the directional movement of activated CXCR3 and CCR5 bearing T cells into the renal allograft and mediates acute rejection. Our data provide a rationale that blocking CXCR3 and CCR5 may offer a unique therapeutic approach to prevent episodes of acute rejection in the early phase after renal transplantation.
BACKGROUND: Experimental studies suggest that the infiltration of activated T cells into the allograft, the key event in the development of acute renal allograft rejection, depends on the expression of chemokines and their interaction with chemokine receptors expressed on T cells. METHODS: For a more detailed comprehension of the pathogenesis of T-cell recruitment in human acute rejection, the in situ expression of chemokines and chemokine receptors in allografts of 26 patients between day 3 and 9 after renal transplantation was examined in the present prospective study. RESULTS: Immunohistochemical staining showed a significantly increased number of CXCR3 (P<0.01) and CCR5 positive T cells (P<0.01) in the tubulointerstitium of patients with acute allograft rejection according to Banff grade Ia-IIb. Likewise the intrarenal RNA expression of the CXCR3 ligands IP-10 (5.2-fold) and I-TAC (7.2-fold) and the CCR5 ligand RANTES (5.7-fold), was significantly up-regulated in rejecting organs. In situ hybridization revealed that IP-10 but not I-TAC was predominantly expressed by infiltrating leukocytes in the tubulointerstitial area, co-localizing with CXCR3 positive T cells. To a lesser degree expression by tubular cells could be detected, providing a possible explanation for the increased urinary IP-10 excretion we found in patients with rejecting organs. CONCLUSIONS: These data from a prospective, biopsy-controlled study indicate that the local expression of IP-10 and RANTES leads to the directional movement of activated CXCR3 and CCR5 bearing T cells into the renal allograft and mediates acute rejection. Our data provide a rationale that blocking CXCR3 and CCR5 may offer a unique therapeutic approach to prevent episodes of acute rejection in the early phase after renal transplantation.
Authors: Leo Boneschansker; Hironao Nakayama; Michele Eisenga; Johannes Wedel; Michael Klagsbrun; Daniel Irimia; David M Briscoe Journal: J Immunol Date: 2016-07-18 Impact factor: 5.422
Authors: Mi Jeong Kim; Roberto Romero; Chong Jai Kim; Adi L Tarca; Sovantha Chhauy; Christopher LaJeunesse; Deug-Chan Lee; Sorin Draghici; Francesca Gotsch; Juan Pedro Kusanovic; Sonia S Hassan; Jung-Sun Kim Journal: J Immunol Date: 2009-03-15 Impact factor: 5.422
Authors: Chong Jai Kim; Roberto Romero; Juan Pedro Kusanovic; Wonsuk Yoo; Zhong Dong; Vanessa Topping; Francesca Gotsch; Bo Hyun Yoon; Je Geun Chi; Jung-Sun Kim Journal: Mod Pathol Date: 2010-03-26 Impact factor: 7.842
Authors: P J E J van de Berg; S L Yong; S D Koch; N Lardy; K A M I van Donselaar-van der Pant; S Florquin; F J Bemelman; R A W van Lier; I J M ten Berge Journal: Clin Exp Immunol Date: 2012-05 Impact factor: 4.330
Authors: A Hoerning; S Köhler; C Jun; J Lu; J Fu; B Tebbe; S Dolff; T Feldkamp; A Kribben; P F Hoyer; O Witzke Journal: Clin Exp Immunol Date: 2012-05 Impact factor: 4.330
Authors: Denise J Lo; Tim A Weaver; David E Kleiner; Roslyn B Mannon; Lynn M Jacobson; Bryan N Becker; S John Swanson; Douglas A Hale; Allan D Kirk Journal: Transplantation Date: 2011-01-15 Impact factor: 4.939
Authors: Vanessa Topping; Roberto Romero; Nandor Gabor Than; Adi L Tarca; Zhonghui Xu; Sun Young Kim; Bing Wang; Lami Yeo; Chong Jai Kim; Sonia S Hassan; Jung-Sun Kim Journal: J Matern Fetal Neonatal Med Date: 2012-11-23
Authors: Namrata G Jain; Elisabeth A Wong; Alexander J Aranyosi; Leo Boneschansker; James F Markmann; David M Briscoe; Daniel Irimia Journal: Integr Biol (Camb) Date: 2015-11 Impact factor: 2.192